Well beyond tomorrow

At SynDermix, our vision is to deliver breakthrough innovation that addresses patient convenience equally well to efficacy and safety in areas of major unmet medical need

SynDermix is a Swiss developer of innovative health technologies that focuses on the development of effective and safe treatments that meaningfully respect patient convenience and address important unmet medical needs.

About us

Latest events and updates

SynDermix Announces Interim Changes to Leadership 20 May, 2020 in Updates

Delegate of the Board and Chief Executive Officer of SynDermix AG, Mr. Dieter Hemmer, on medical leave of absence; Dr. Konstantinos Efthymiopoulos appointed Designated Managing Director until the AGM 2020

Update on the Clinical Trial of the SDX-3101 Medical Device 7 April, 2020 in Updates

SynDermix AG announced temporary postponement of initiation of the SDX-3101 clinical trial on chronic rhinosinusitis without nasal polyps due to the novel coronavirus pandemic. (more…)

First Site Initiation Visit (SIV) Completed for the Clinical Trial of SDX-3101 in Austria 7 January, 2020 in Updates

SynDermix AG is pleased to announce the successful completion of the first SIV for the clinical trial of SDX-3101, in preparation for the recruitment of the first patient to the study. (more…)

Our platform technologies